Dogwood Therapeutics (DWTX) Change in Account Payables (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Change in Account Payables of -$589511.0 for Q1 2026, down 348.38% year-over-year from $237346.4 in Q1 2025, and down 595.53% quarter-over-quarter from $118965.0 in Q4 2025.
Dogwood Therapeutics (DWTX) Change in Account Payables (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Change in Account Payables for 7 consecutive years, with -$589511.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 348.38% year-over-year to -$589511.0; the TTM figure through Mar 2026 stood at -$990641.0 (down 27887.97% YoY), while the FY2025 annual figure was -$532607.0, down 342.22% from the prior year.
- Change in Account Payables retreated to -$589511.0 in Q1 2026 per DWTX's latest filing, from $118965.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $334848.0 in Q2 2022 and bottomed at -$606829.0 in Q2 2025.
- Historically, Change in Account Payables has averaged -$67304.7 across 5 years, with a median of -$23173.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Account Payables sank 1790.43% — and 2024, when it jumped 3540.32%.
- Dogwood Therapeutics' Change in Account Payables stood at -$72572.0 in 2022, then slipped by 28.78% to -$93456.0 in 2023, then plunged by 31.79% to -$123161.0 in 2024, then jumped by 196.59% to $118965.0 in 2025, then plunged by 595.53% to -$589511.0 in 2026.
- Business Quant data shows DWTX's Change in Account Payables at -$589511.0 in Q1 2026, $118965.0 in Q4 2025, and $86734.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 263,650.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -589,511.00 |
| Mar 31, 2026 | -589,511.00 |
| Dec 31, 2025 | 118,965.00 |
| Dec 31, 2025 | 118,965.00 |
| Sep 30, 2025 | 86,734.00 |
| Sep 30, 2025 | 86,734.00 |
| Jun 30, 2025 | -606,829.00 |
| Jun 30, 2025 | -606,829.00 |
| Mar 31, 2025 | -131,477.00 |
| Mar 31, 2025 | -131,477.00 |
| Dec 31, 2024 | -123,161.00 |
| Dec 31, 2024 | -123,161.00 |
| Sep 30, 2024 | 307,427.00 |
| Sep 30, 2024 | 307,427.00 |
| Jun 30, 2024 | -49,224.00 |
| Jun 30, 2024 | -49,224.00 |
| Mar 31, 2024 | 84,846.00 |
| Mar 31, 2024 | 84,846.00 |
| Dec 31, 2023 | -93,456.00 |
| Dec 31, 2023 | -93,456.00 |